AvKARE Recalled One Lot of Atovaquone Oral Suspension

April 05, 2024

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.

On April 1, 2024, AvKARE recalled one lot of atovaquone oral suspension, an antiprotozoal agent used to prevent and treat Pneumocystis jiroveci pneumonia (PCP) for patients who are 13 years of age and older and who are unable to use other medicines. Possible microbial contamination in the recalled product could cause severe, potentially fatal, infections for patients exposed to it. The FDA notice has more information.

Last updated: April 05, 2024

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.